RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cytokinetics - Stock

Cytokinetics EBIT 2024

Cytokinetics EBIT

-481.72 M USD

Ticker

CYTK

ISIN

US23282W6057

WKN

A1W1KK

In 2024, Cytokinetics's EBIT was -481.72 M USD, a -2.92% increase from the -496.21 M USD EBIT recorded in the previous year.

The Cytokinetics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e566.57
2027e93.65
2026e-256.18
2025e-461.75
2024e-481.72
2023-496.21
2022-324.2
2021-186.3
2020-93.9
2019-98.9
2018-88.9
2017-113.4
201618.7
2015-37.4
2014-14.8
2013-33.9
2012-40.6
2011-46.8
2010-49.6
200926.1
2008-56.6
2007-56.5
2006-61.3
2005-44.6
2004-38.4

Cytokinetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cytokinetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cytokinetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cytokinetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cytokinetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cytokinetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cytokinetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cytokinetics’s growth potential.

Cytokinetics Revenue, Profit, and EBIT History

DateCytokinetics RevenueCytokinetics EBITCytokinetics Net Income
2029e2.3 B undefined0 undefined833.33 M undefined
2028e1.64 B undefined566.57 M undefined547.82 M undefined
2027e979.7 M undefined93.65 M undefined177.17 M undefined
2026e372.92 M undefined-256.18 M undefined-296.91 M undefined
2025e84.29 M undefined-461.75 M undefined-514.72 M undefined
2024e14.67 M undefined-481.72 M undefined-535.46 M undefined
20237.53 M undefined-496.21 M undefined-526.24 M undefined
202294.6 M undefined-324.2 M undefined-389 M undefined
202170.4 M undefined-186.3 M undefined-215.3 M undefined
202055.8 M undefined-93.9 M undefined-127.3 M undefined
201926.9 M undefined-98.9 M undefined-121.7 M undefined
201831.5 M undefined-88.9 M undefined-106.3 M undefined
201713.4 M undefined-113.4 M undefined-127.8 M undefined
2016106.4 M undefined18.7 M undefined16.5 M undefined
201528.7 M undefined-37.4 M undefined-37.5 M undefined
201446.9 M undefined-14.8 M undefined-14.6 M undefined
201330.6 M undefined-33.9 M undefined-33.7 M undefined
20127.6 M undefined-40.6 M undefined-41.7 M undefined
20114 M undefined-46.8 M undefined-50.7 M undefined
20102.6 M undefined-49.6 M undefined-49.3 M undefined
200981.5 M undefined26.1 M undefined24.5 M undefined
200812.4 M undefined-56.6 M undefined-56.4 M undefined
200713.6 M undefined-56.5 M undefined-48.9 M undefined
20063.1 M undefined-61.3 M undefined-57.1 M undefined
20058.9 M undefined-44.6 M undefined-42.3 M undefined
200413.4 M undefined-38.4 M undefined-37.2 M undefined

Cytokinetics stock margins

The Cytokinetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cytokinetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cytokinetics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cytokinetics's sales revenue. A higher gross margin percentage indicates that the Cytokinetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cytokinetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cytokinetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cytokinetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cytokinetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cytokinetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cytokinetics Margin History

Cytokinetics Gross marginCytokinetics Profit marginCytokinetics EBIT marginCytokinetics Profit margin
2029e0 %0 %36.22 %
2028e0 %34.61 %33.46 %
2027e0 %9.56 %18.08 %
2026e0 %-68.69 %-79.62 %
2025e0 %-547.83 %-610.68 %
2024e0 %-3,284.41 %-3,650.8 %
20230 %-6,589.71 %-6,988.63 %
20220 %-342.71 %-411.21 %
20210 %-264.63 %-305.82 %
20200 %-168.28 %-228.14 %
20190 %-367.66 %-452.42 %
20180 %-282.22 %-337.46 %
20170 %-846.27 %-953.73 %
20160 %17.58 %15.51 %
20150 %-130.31 %-130.66 %
20140 %-31.56 %-31.13 %
20130 %-110.78 %-110.13 %
20120 %-534.21 %-548.68 %
20110 %-1,170 %-1,267.5 %
20100 %-1,907.69 %-1,896.15 %
20090 %32.02 %30.06 %
20080 %-456.45 %-454.84 %
20070 %-415.44 %-359.56 %
20060 %-1,977.42 %-1,841.94 %
20050 %-501.12 %-475.28 %
20040 %-286.57 %-277.61 %

Cytokinetics Aktienanalyse

What does Cytokinetics do?

Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Cytokinetics's EBIT

Cytokinetics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Cytokinetics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Cytokinetics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Cytokinetics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Cytokinetics Stock

How much did Cytokinetics achieve in EBIT for the current year?

In the current year, Cytokinetics has achieved an EBIT of -481.72 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Cytokinetics.

How has the EBIT of Cytokinetics developed in recent years?

The EBIT of Cytokinetics has increased by -2.918% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Cytokinetics?

The EBIT of Cytokinetics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Cytokinetics pay?

Over the past 12 months, Cytokinetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cytokinetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cytokinetics?

The current dividend yield of Cytokinetics is .

When does Cytokinetics pay dividends?

Cytokinetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cytokinetics?

Cytokinetics paid dividends every year for the past 0 years.

What is the dividend of Cytokinetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cytokinetics located?

Cytokinetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cytokinetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cytokinetics from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Cytokinetics pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Cytokinetics in the year 2023?

In the year 2023, Cytokinetics distributed 0 USD as dividends.

In which currency does Cytokinetics pay out the dividend?

The dividends of Cytokinetics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cytokinetics

Our stock analysis for Cytokinetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytokinetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.